GlassScriptPhysician profile
Angela D Watson
NPI 1275601346
$32,344.47
in general payments reported to CMS, 2019-2025
45 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $1,855 · 2021: $1,391 · 2022: $1,151 · 2023: $993 · 2024: $1,214 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $5,319 · Food and Beverage: $4,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,800.00 |
| Travel and Lodging | $5,319.11 |
| Food and Beverage | $4,069.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23,379.58 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Merz North America, INC. | $1,371.57 | 2020-2022 | |
| Novo Nordisk INC | $1,035.10 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $613.92 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $562.63 | 2023-2025 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $498.96 | 2019-2025 | |
| Pfizer INC. | $466.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $458.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $410.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $402.91 | 2019-2022 | |
| Ucb, INC. | $392.69 | 2019-2025 | Nayzilam, Briviact |
| Sunovion Pharmaceuticals INC. | $344.09 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.89 | 2020-2025 | Jardiance |
| Abbott Laboratories | $220.33 | 2021-2025 | Freestyle Libre, Freestyle Libre 3, Proclaim |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.